
1. Malar J. 2019 Apr 10;18(1):126. doi: 10.1186/s12936-019-2756-4.

African isolates show a high proportion of multiple copies of the Plasmodium
falciparum plasmepsin-2 gene, a piperaquine resistance marker.

Leroy D(1), Macintyre F(2), Adoke Y(3), Ouoba S(4), Barry A(4), Mombo-Ngoma
G(5)(6), Ndong Ngomo JM(7), Varo R(8)(9)(10), Dossou Y(11), Tshefu AK(12), Duong 
TT(13), Phuc BQ(14), Laurijssens B(15), Klopper R(16), Khim N(17), Legrand E(18),
Ménard D(19).

Author information: 
(1)Medicines for Malaria Venture, Geneva, Switzerland. leroyd@mmv.org.
(2)Medicines for Malaria Venture, Geneva, Switzerland.
(3)Infectious Diseases Research Collaboration, Tororo Hospital, Tororo, Uganda.
(4)Institut de Recherche en Sciences de la Santé - Unité de Recherche Clinique de
Nanoro, Ouagadougou, Burkina Faso.
(5)Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
(6)Institut für Tropenmedizin, Universität Tübingen, Tübingen, Germany.
(7)Département de Parasitologie, Université des Sciences de la Santé Gabon,
Libreville, Gabon.
(8)ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic -
Universitat de Barcelona, Barcelona, Spain.
(9)Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
(10)ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain.
(11)Centre de Recherche sur le Paludisme Associé à la Grossesse et l'Enfance,
Faculté Des Sciences De La Santé, Cotonou, Benin.
(12)Centre de Recherche du Centre Hospitalier de Mont Amba, Kinshasa School of
Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the
Congo.
(13)National Institute of Malariology, Parasitology and Entomology, Hanoi,
Vietnam.
(14)Clinical Pharmaceutical Research Department, National Institute of
Malariology, Parasitology and Entomology, 35 Trung Van Street, Nam Tu Liem
District, Hanoi, Vietnam.
(15)BEL Pharm Consulting, Nîmes, France.
(16)Clindata Pty Ltd, Bloemfontein, South Africa.
(17)Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom
Penh, Cambodia.
(18)Malaria Genetics and Resistance Group, INSERM U1201-CNRS ERL919, Institut
Pasteur, Paris, France.
(19)Malaria Genetics and Resistance Group, INSERM U1201-CNRS ERL919, Institut
Pasteur, Paris, France. dmenard@pasteur.fr.

BACKGROUND: Today, the development of new and well-tolerated anti-malarial drugs 
is strongly justified by the emergence of Plasmodium falciparum resistance. In
2014-2015, a phase 2b clinical study was conducted to evaluate the efficacy of a 
single oral dose of Artefenomel (OZ439)-piperaquine (PPQ) in Asian and African
patients presenting with uncomplicated falciparum malaria.
METHODS: Blood samples collected before treatment offered the opportunity to
investigate the proportion of multidrug resistant parasite genotypes, including
P. falciparum kelch13 mutations and copy number variation of both P. falciparum
plasmepsin 2 (Pfpm2) and P. falciparum multidrug resistance 1 (Pfmdr1) genes.
RESULTS: Validated kelch13 resistance mutations including C580Y, I543T, P553L and
V568G were only detected in parasites from Vietnamese patients. In Africa,
isolates with multiple copies of the Pfmdr1 gene were shown to be more frequent
than previously reported (21.1%, range from 12.4% in Burkina Faso to 27.4% in
Uganda). More strikingly, high proportions of isolates with multiple copies of
the Pfpm2 gene, associated with piperaquine (PPQ) resistance, were frequently
observed in the African sites, especially in Burkina Faso and Uganda (> 30%).
CONCLUSIONS: These findings were considered to sharply contrast with the recent
description of increased sensitivity to PPQ of Ugandan parasite isolates. This
emphasizes the necessity to investigate in vitro susceptibility profiles to PPQ
of African isolates with multiple copies of the Pfpm2 gene and estimate the risk 
of development of PPQ resistance in Africa. Trial registration Clinicaltrials.gov
reference: NCT02083380. Study title: Phase II efficacy study of artefenomel and
piperaquine in adults and children with P. falciparum malaria.
https://clinicaltrials.gov/ct2/results?cond=&term=NCT02083380&cntry=&state=&city=
&dist= . FSFV: 23-Jul-2014; LSLV: 09-Oct-2015.

DOI: 10.1186/s12936-019-2756-4 
PMCID: PMC6457011
PMID: 30967148  [Indexed for MEDLINE]

